Sutro Biopharma retains stock target with Buy rating on key ...

Oct 11, 2024 · On Friday, H.C. Wainwright reaffirmed its positive stance on Sutro Biopharma (NASDAQ: STRO) shares, maintaining a Buy rating with a $12.00 price target. The …

$12.00
OFF

Sutro Biopharma Retains Stock Target With Buy Rating On Key ...

2 weeks from now

Oct 11, 2024 · On Friday, H.C. Wainwright reaffirmed its positive stance on Sutro Biopharma (NASDAQ: STRO) shares, maintaining a Buy rating with a $12.00 price target. The …

investing.com

$17
OFF

Strong Buy Rating For Sutro Biopharma Amid Promising Trial …

2 weeks from now

Dec 11, 2024 · Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of $17.0...

businessinsider.com

$15.00
OFF

Sutro Biopharma Retains Stock Target With Buy Rating On Key ...

2 weeks from now

Oct 11, 2024 · Truist Securities adjusted the company's stock price target to $15.00, while maintaining a Buy rating. Sutro Biopharma is also progressing with the enrollment of …

investing.com

$2
OFF

Why Did BofA Securities Give Sutro Biopharma Inc (STRO) Stock …

2 weeks from now

Nov 20, 2024 · Sutro Biopharma Inc (STRO) Stock Trading Recap. On Tuesday, Sutro Biopharma Inc (STRO) stock saw a decline, ending the day at $2.7 which represents a decrease of $-0.05 …

bovnews.com

$12
OFF

Sutro Biopharma Shares Rise On BofA Buy Rating, $12 Target

2 weeks from now

May 8, 2024 · Wednesday, BofA Securities initiated coverage on Sutro Biopharma (NASDAQ: NASDAQ: STRO), a company focused on the development of cancer therapeutics, with a Buy …

investing.com

$17.00
OFF

Strong Buy Rating For Sutro Biopharma On Promising Clinical Data …

2 weeks from now

Sep 15, 2024 · JMP Securities analyst Reni Benjamin reiterated a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $17.00.. Reni Benjamin has given …

businessinsider.com

$12.00
OFF

Sutro Biopharma Retains Stock Target With Buy Rating On Key ...

2 weeks from now

On Friday, H.C. Wainwright reaffirmed its positive stance on Sutro Biopharma (NASDAQ:STRO) shares, maintaining a Buy rating with a $12.00 price target. The endorsement follows Sutro's …

investing.com

$12.00
OFF

BofA Maintains Buy Rating On Sutro Shares - Investing.com

2 weeks from now

Oct 11, 2024 · BofA Securities has kept its Buy rating and $12.00 price target for Sutro Biopharma (NASDAQ: NASDAQ: STRO), a clinical-stage drug discovery, development, and …

investing.com

$17.00
OFF

Sutro Biopharma’s Promising Market Expansion And Financial …

2 weeks from now

Nov 14, 2024 · JMP Securities analyst Reni Benjamin reiterated a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $17.00.. Reni Benjamin has given …

businessinsider.com

$11.50
OFF

What Is The Current Price Target And Forecast For Sutro Biopharma …

2 weeks from now

6 days ago · Based on short-term price targets offered by 10 analysts, the average price target for Sutro Biopharma, Inc. comes to $11.50. The forecasts range from a low of $4.00 to a high of …

zacks.com

$12.00
OFF

A Glimpse Into The Expert Outlook On Sutro Biopharma Through …

2 weeks from now

Nov 18, 2024 · Rating Current Price Target Prior Price Target; Andrew Fein: HC Wainwright & Co. Maintains: Buy: $12.00: $12.00: Edward Tenthoff: ... providing estimates for the future value of …

nasdaq.com

$11.00
OFF

Piper Sandler Sticks To Its Buy Rating For Sutro Biopharma (STRO)

2 weeks from now

Oct 11, 2024 · In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $11.00.The …

businessinsider.com

35%
OFF

Truist Financial Reaffirms Their Buy Rating On Sutro Biopharma …

2 weeks from now

Oct 21, 2024 · The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma with a $10.83 average price target, representing a 190.35% upside.

businessinsider.com

FAQs about Sutro Biopharma retains stock target with Buy rating on key ... Coupon?

Should you buy Sutro Biopharma (Stro – research report)?

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $17.00. Reni Benjamin has given his Buy rating due to a combination of factors that strongly indicate positive potential for Sutro Biopharma’s stock. ...

What is Sutro Biopharma?

The collection can be rapidly screened to identify the best sites of attachment for antibody–drug combinations or long-acting protein therapies. Sutro Biopharma, Inc. is a public biotechnology company located in South San Francisco. The company is mainly focusing on clinical-stage drug discovery, development, and manufacturing. ...

How much debt does Sutro Biopharma have?

Sutro Biopharma had US$25.3m of debt, as of March 2022, which is approximately the same as the previous year. However, it also had US$209.1m in cash, resulting in net cash of US$183.9m. ...

Does Sutro Biopharma have a partnership with Merck?

Sutro Biopharma has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders. ...

Why did Reni Benjamin buy Sutro Biopharma?

Reni Benjamin has given his Buy rating due to a combination of factors that highlight Sutro Biopharma’s promising prospects. The company has demonstrated progress through its strategic expansion of luvelta into the NSCLC space, which signifies its potential to capture a broader market. ...